Reimbursement is the gate, not the finish line
Why German reimbursement strategy must be designed before — not after — your clinical evidence plan, and how it shapes pricing and adoption.
Read insightInsights
Concrete, healthcare-specific thinking on reimbursement, KOL engagement, distributor development, clinical evidence and commercial execution in Germany.
Why German reimbursement strategy must be designed before — not after — your clinical evidence plan, and how it shapes pricing and adoption.
Read insightThe structural reasons international MedTech companies lose traction with German distributors — and how qualification and performance management fix it.
Read insightBuilding clinical credibility in Germany means structured validation with the physicians who decide adoption — not collecting names.
Read insightWhy the gap between a German market-entry strategy and commercial results is where most MedTech companies stall — and how local execution closes it.
Read insightHow PMCF and real-world evidence programmes connect commercial adoption to the evidence payers and hospitals actually require in Germany.
Read insightA structured way to identify why adoption and revenue are below expectation — and the go-to-market reset that rebuilds traction.
Read insight